Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

(2019) Richard Gray et al.   LANCET

Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer – Results from the prospective multi-center randomized ADEBAR trial

(2016) Lukas Schwentner et al.   BREAST

Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer

(2016) Theodoros Foukakis et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

(2013)   LANCET

Tailored chemotherapy doses based on toxicity in breast cancer result in similar quality of life values, irrespective of given dose levels

(2011) Mariann Iiristo et al.   ACTA ONCOLOGICA

Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007

(2008) Ali Montazeri   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH